Iceland· IS-EU/1/19/1417/002

Beovu

A brolucizumab product containing brolucizumabum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 13 of our 19 countries.

ATC S01LA06

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedBeovuATCS01LA06REGISTER NO.IS-EU/1/19/1417/002PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Brolucizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC S01LA06 (brolucizumab), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 8 of them publish a price we can compare per daily dose

Brolucizumab · ATC S01LA06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Brolucizumabum INN
Manufacturer
Novartis Europharm Limited*
Country
Iceland (IS)
ATC code
S01LA06
ATC class
Brolucizumab
Defined daily dose
0.0357 DE, IVT
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d6934af4-27c3-4cd8-8a54-52c7529a9361
GET /v1/drugs/d6934af4-27c3-4cd8-8a54-52c7529a9361?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "S01LA06",
  "marketed": false,
  "strength": "120 mg/ml",
  "ma_number": "EU/1/19/1417/002",
  "substance": "Brolucizumabum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "43874"
}

See everything about brolucizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.